论文部分内容阅读
目的探讨培美曲塞二钠联合顺铂治疗晚期非鳞非小细胞肺癌的临床疗效及安全性。方法 72例晚期非鳞非小细胞肺癌患者,根据不同治疗方案分为观察组与对照组,各36例。对照组给予培美曲塞二钠治疗,观察组给予培美曲塞二钠+顺铂治疗。对比两组临床疗效及不良反应发生率。结果观察组治疗总有效率为47.22%,疾病控制率为88.89%,均显著高于对照组的25.00%、69.44%(P<0.05);观察组不良反应发生率为22.22%,与对照组的16.67%比较,差异无统计学意义(P>0.05)。结论给予晚期非鳞非小细胞肺癌患者培美曲塞二钠与顺铂联合治疗,临床效果显著,且不会增加患者不良反应,具有一定安全性。
Objective To investigate the clinical efficacy and safety of pemetrexed disodium combined with cisplatin in the treatment of advanced non-squamous non-small cell lung cancer. Methods 72 cases of advanced non-squamous non-small cell lung cancer patients were divided into observation group and control group according to different treatment regimen, 36 cases in each. The control group received pemetrexed disodium treatment, and the observation group received pemetrexed disodium + cisplatin treatment. The clinical efficacy and incidence of adverse reactions in both groups were compared. Results The total effective rate of observation group was 47.22%, disease control rate was 88.89%, which were significantly higher than that of control group (25.00%, 69.44%, P <0.05). The incidence of adverse reactions in observation group was 22.22% 16.67%, the difference was not statistically significant (P> 0.05). Conclusions The combination therapy of pemetrexed disodium and cisplatin in patients with advanced non-squamous non-small cell lung cancer has a significant clinical effect and does not increase adverse reactions in patients with certain safety.